Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamins and the skin: Vitamin C in dermatology.

Clinics in dermatology·2026
Same author

From significance to relevance: raising the bar for harm in dermatology.

The British journal of dermatology·2025
Same author

Potpourri V: Dermatology at the crossroads of science, society, and history.

Clinics in dermatology·2025
Same author

Clinical, histopathologic, and immunohistochemical patterns of cutaneous leishmaniasis.

Clinics in dermatology·2025
Same author

Innovations and Insights from the 16th World Congress of the International Academy of Cosmetic Dermatology held in Budapest, Hungary, June 26 to 28, 2025.

Clinics in dermatology·2025
Same author

Angioinvasive Scopulariopsis infection.

JAAD case reports·2025
Same journal

A 25-year evolution of systemic mastocytosis to mast cell leukemia: Cutaneous clues.

JAAD case reports·2026
Same journal

Bullous immunoglobulin A dermatosis following oral contrast in a patient with dermatitis herpetiformis.

JAAD case reports·2026
Same journal

Vohwinkel syndrome: Clinical and genetic insights from 26 years of follow-up.

JAAD case reports·2026
Same journal

Familial benign recurrent acral pigmentation: A rare presentation.

JAAD case reports·2026
Same journal

Refractory chronic lymphocytic leukemia-associated pruritus successfully treated with nemolizumab.

JAAD case reports·2026
Same journal

Epidermolysis bullosa acquisita improved with use of dupilumab.

JAAD case reports·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

13.3K

Oral plasma cell mucositis

Jahleel Perrin1, Hiren Kolli2, Brigitte Utter2

  • 1University of Illinois, College of Medicine, Chicago, Illinois.

JAAD Case Reports
|November 19, 2025
PubMed
Summary

No abstract available in PubMed .

Keywords:
oral mucositisplasma cell mucositisstomatodyniatongue enlargement

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.5K

Related Experiment Videos

Last Updated: Jan 11, 2026

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

13.3K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.5K